Exome Asset Management sold its 421,488-share stake in Wave Life Sciences after the obesity drug miss. The $5.5M exit raises the question: is there a floor below $6.90?
On May 15, 2026, Exome Asset Management filed an SEC 13F revealing it sold its entire stake in Wave Life Sciences (NASDAQ:WVE). The fund liquidated 421,488 shares worth an estimated $5.49 million, calculated using the average closing price during the first quarter of 2026. The quarter-end value of Exome’s position in WVE dropped by $7.17 million, a figure that includes both trading activity and price depreciation.
The exit is complete. Exome no longer holds WVE in any form. The fund’s prior position represented 3.4% of its total AUM, making WVE its fifth-largest holding at the end of Q4 2025. Now that slot is empty.
The SEC filing is unambiguous. Exome Asset Management LLC sold all 421,488 shares of Wave Life Sciences during the first quarter of 2026. The estimated transaction value of $5.49 million is derived from the average quarterly price, which means actual cash proceeds could differ slightly depending on execution timing.
The simple interpretation: A smart-money biotech fund saw the 50% crash in March and dumped the stock. The better read: Exome sold ahead of or immediately after the crash, taking a loss rather than waiting for a recovery. The $7.17 million quarter-end value drop – from a much larger starting point – suggests massive price erosion ate into the position before Exome could fully exit. This is not a strategic pivot away from oligonucleotide platforms. It is a specific risk verdict on Wave Life Sciences.
Exome’s remaining top holdings tell the story:
Each of these is a clinical-stage biotech. Exome is not retreating from the space. It is exiting Wave specifically.
The single most consequential event for Wave in 2026 came in late March. The company released data from a higher-dose cohort of its obesity candidate WVE-007. The drug failed to show meaningful improvement in reducing visceral adipose tissue – a key type of belly fat. Shares collapsed roughly 50% in one session, erasing nearly half the company’s market value.
WVE-007 is designed to target RNA transcripts involved in metabolic regulation. The miss on visceral fat raises questions about the platform’s applicability in metabolic disease. Wave’s PRISM platform has produced success in other areas, obesity is a high-stakes field dominated by Novo Nordisk and Eli Lilly. A small biotech with a miss on a measurable metabolic endpoint invites skepticism across the entire pipeline.
Wave’s other clinical candidates include WVE-004 (for ALS/FTD), WVE-003 (Huntington’s disease), and WVE-N531 (Duchenne muscular dystrophy). None are obesity, the platform doubt spills over. The stock closed at $6.90 on May 14, up 8% over the prior year. It underperformed the S&P 500 by nearly 20 percentage points. The market has re-priced Wave based on the WVE-007 failure, not its broader pipeline.
Wave Life Sciences released first-quarter 2026 earnings after the crash. The numbers show a company in transition:
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $38.2 million | $9.2 million |
| Net loss | $(26.1 million) | $(46.9 million) |
| Cash and equivalents | $544.6 million | Not disclosed |
The revenue jump appears to come from partnership milestones. The net loss narrowed significantly. The $544.6 million cash position is the critical buffer: management expects that funding to last into the third quarter of 2028.
A long cash runway removes financing risk. Wave is unlikely to need a dilutive equity raise in the next two years. Revenue from partnerships is lumpy and not a guaranteed recurring stream. The Q1 beat was driven by milestone payments from existing collaborations, not product sales. For a clinical-stage company, cash is survival capital. At $544.6 million, Wave has breathing room to run multiple trials without immediate fundraising pressure.
A closer look: the operating burn rate – estimated around $30 million to $40 million per quarter based on the $26.1 million net loss and cash trajectory – means the company will consume roughly $300 million to $400 million over the next three years. That leaves a comfortable margin, one that assumes no major trial cost overruns.
Exome is a dedicated biotech fund with a concentrated portfolio. Exiting WVE entirely while still holding IONS, PRAX, COGT, and ELVN signals a company-specific concern, not a sector-wide rejection of early-stage biotech.
The failure of WVE-007 to improve visceral fat is a cautionary data point for any small-cap biotech claiming an obesity asset. The market has become highly skeptical of non-incremental approaches to weight loss. Wave’s miss will cause investors to scrutinize other early-stage metabolic candidates more closely. Expect increased discounting on any obesity-focused biotech with early-phase data.
Exome retains an $8.26 million position in Ionis Pharmaceuticals (NASDAQ:IONS), another oligonucleotide platform company. Ionis has a more mature pipeline with commercial royalties from Spinraza and late-stage assets. The contrast shows that Exome is not abandoning RNA-targeted therapy as a mechanism – it is making a bet on execution. Ionis has a longer track record and a clearer regulatory path.
AlphaScala’s proprietary score for IONS is currently Unscored (Alpha Score unavailable), reflecting limited coverage data. The stock page is available at IONS stock page for reference.
For Wave Life Sciences, the next meaningful driver will be clinical and regulatory execution, not institutional trading activity. Exome’s exit removes one supportive holder, the stock at $6.90 may already be in weaker hands.
Practical rule: When a dedicated biotech fund exits a position entirely after a 50% clinical crash, the assumption should be that the risk-reward does not favor holding through the next data cycle. Unless new clinical evidence emerges, the stock lacks a near-term catalyst.
Exome’s exit is a signal, the real story is the March crash and the subsequent pipeline uncertainty. Wave Life Sciences remains a high-risk, high-reward biotech play with a long cash runway. The next meaningful data point – from WVE-007’s accelerated program or another pipeline asset – will determine whether the stock recovers or continues to drift.
For broader market context, see stock market analysis and the IONS stock page for comparison.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.